drug · antibody
mirikizumab
Marketedupdated 5mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
indications
investigational
IBD (Crohn's + UC)
targets
Interleukin-23
all catalysts(5)
approval · 5
Oct 26, 2023
approval
$LLY1183.46+0.13%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Apr 29, 2024
approval
$LLY1183.46+0.13%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
$LLY1183.46+0.13%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
$LLY1183.46+0.13%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Oct 23, 2025
approval
$LLY1183.46+0.13%
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Trials studying mirikizumab
- phase2LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- phase4MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
- phase3A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- phase2A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- —VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
- phase3Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- phase2A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- phase3A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that